Therefore, in this study, we investigated the association between TP53 mutations and immunotherapy outcomes of NSCLC patients in a cohort of 350 metastatic or unresectable NSCLC patients who were treated with immunotherapies. This evidence concerns the gene TP53 and non-small cell lung carcinoma.